SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

BriaCell Therapeutics Corp.
Date: Jan. 8, 2026 · CIK: 0001610820 · Accession: 0001493152-26-000961

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-292388

Date
Jan. 8, 2026
Author
Chief
Form
CORRESP
Company
BriaCell Therapeutics Corp.

Letter

BriaCell Therapeutics Corp.

Suite 300 - 235 15th Street

West Vancouver, BC V7T 2X1

January 8, 2026

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street NE

Washington, D.C. 20549

Attention: Daniel Crawford

Re: BriaCell Therapeutics Corp. (the "Company")

Registration Statement on Form S-1 (the "Registration Statement")

File No. 333-292388

Ladies and Gentlemen:

The Company hereby withdraws its request for an accelerated effective date of the above-referenced Registration Statement to 5:00 p.m. Eastern Time on January 8, 2026, or as soon as practicable thereafter.

In addition, the Company hereby requests that the effective date of the above-referenced Registration Statement be accelerated to 5:00 p.m. Eastern Time on January 13, 2026, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time pursuant to Rule 461 under the Securities Act of 1933, as amended.

Once the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference Carmel LLP, by contacting Christian Lichtenberger, Esq. at (212) 997-0962 or clichtenberger@srfc.law.

Very
truly yours,
/s/
William V. Williams

Show Raw Text
CORRESP
 1
 filename1.htm

 BriaCell
Therapeutics Corp.

 Suite
300 - 235 15th Street

 West
Vancouver, BC V7T 2X1

 January
8, 2026

 VIA
EDGAR

 U.S.
Securities and Exchange Commission

 Division
of Corporation Finance

 100
F Street NE

 Washington,
D.C. 20549

 Attention:
Daniel Crawford

 Re:
 BriaCell
 Therapeutics Corp. (the "Company")

 Registration
 Statement on Form S-1 (the "Registration Statement")

 File
 No. 333-292388

 Ladies
and Gentlemen:

 The
Company hereby withdraws its request for an accelerated effective date of the above-referenced Registration Statement to 5:00 p.m. Eastern
Time on January 8, 2026, or as soon as practicable thereafter.

 In
addition, the Company hereby requests that the effective date of the above-referenced Registration Statement be accelerated to 5:00 p.m.
Eastern Time on January 13, 2026, or as soon as practicable thereafter, unless the Company notifies you otherwise prior to such time
pursuant to Rule 461 under the Securities Act of 1933, as amended.

 Once
the Registration Statement has been declared effective, please confirm orally that event with our counsel, Sichenzia Ross Ference Carmel
LLP, by contacting Christian Lichtenberger, Esq. at (212) 997-0962 or clichtenberger@srfc.law.

 Very
 truly yours,

 /s/
 William V. Williams

 William
 V. Williams

 Chief
 Executive Officer